Indolent non-Hodgkin lymphoma (NHL) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Indolent NHL is a slow-growing type of NHL, and the common subtypes of indolent NHL include follicular lymphoma (FL) and marginal zone lymphoma. Conventional therapy considers advanced-stage indolent or follicular non-Hodgkin lymphoma (NHL) incurable. However, only localized stage I or II follicular lymphoma may occasionally be cured with radiotherapy of involved sites. Indolent NHL usually responds well to treatment and can often be controlled for many years. Some people with indolent NHL never require treatment. Indolent NHL tends to come back (recur) after treatment. It can also become resistant to treatment over time. Some indolent NHLs can also change into a more aggressive type of NHL and be treated as that type of NHL. Some indolent NHLs grow slowly and may spread to different body parts.

 

Indolent NHL represents 40% of all NHL diagnosed cases; NHL’s overall five-year survival rate is 71% on average and can be as high as 95% for certain types of indolent and localized. Survival rates vary widely for different types and stages of lymphoma.

 

The competitive landscape of Indolent non-Hodgkin lymphoma (NHL) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Indolent non-Hodgkin lymphoma (NHL) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Indolent non-Hodgkin lymphoma (NHL) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Indolent non-Hodgkin lymphoma (NHL) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Duvelisib           SecuraBio         Phase 2

2          Selinexor (ATG-010)     Antengene Corporation Limited  Phase 1/2

3          Yescarta (axicabtagene ciloleucel)          Kite, a Gilead Company            Phase 2

4          Bendamustine   Lundbeck Canada Inc.   Phase 3

5          Obinutuzumab and Ibrutinib       Genentech, Inc. Phase 2

6          Inotuzumab Ozogamicin (CMC-544)       Pfizer    Phase 2

7          IBI376  Innovent Biologics (Suzhou) Co. Ltd.      Phase 2

8          Tenalisib           Rhizen Pharmaceuticals SA       Phase 2

9          Bendamustine hydrochloride      Teva Branded Pharmaceutical            Phase 3

10        Lenalidomide and Rituximab      Celgene            Phase 2

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more